← Back to Clinical Trials
Recruiting NCT05820919

NCT05820919 Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05820919
Status Recruiting
Phase
Sponsor University of Alabama, Tuscaloosa
Condition Alzheimer Disease
Study Type INTERVENTIONAL
Enrollment 456 participants
Start Date 2023-09-07
Primary Completion 2026-04-01

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
LOCK Sleep ProgramNo intervention (control period/baseline data collection)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 456 participants in total. It began in 2023-09-07 with a primary completion date of 2026-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study seeks to improve clinical outcomes for an important, growing, and vulnerable population-nursing home residents with Alzheimer's disease or related dementias-by testing an evidence-based intervention to improve these residents' sleep. It will also examine the implementation and sustainment of this intervention.

Eligibility Criteria

Inclusion Criteria: * Nursing home residents aged \>=50 years with an Alzheimer disease or related dementia (ADRD) diagnosis, identified by nursing home staff participating in frontline LOCK sleep huddles as having sleep problems Exclusion Criteria: * Residents with a high risk of OSA who are not being treated for OSA because actigraph measurements are inaccurate in that population. * Residents who have a persistent bilateral resting tremor or paralysis in both arms (a subset of persons with Parkinson's disease and related significant tremor-causing diagnoses), due to actigraph measurement inaccuracies

Contact & Investigator

Central Contact

Lynn Snow, PhD

✉ LSNOW@ua.edu

📞 205-201-0312

Principal Investigator

Lynn Snow, PhD

PRINCIPAL INVESTIGATOR

The University of Alabama

Frequently Asked Questions

Who can join the NCT05820919 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05820919 currently recruiting?

Yes, NCT05820919 is actively recruiting participants. Contact the research team at LSNOW@ua.edu for enrollment information.

Where is the NCT05820919 trial being conducted?

This trial is being conducted at Lakewood, United States, Murfreesboro, United States, San Marcos, United States.

Who is sponsoring the NCT05820919 clinical trial?

NCT05820919 is sponsored by University of Alabama, Tuscaloosa. The principal investigator is Lynn Snow, PhD at The University of Alabama. The trial plans to enroll 456 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology